Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study

被引：0
|
作者：
Zhang, Lulu [1 ]
Zhou, Lijia [1 ]
Shi, Yanxia [1 ]
An, Xin [1 ]
机构：
[1] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Canc Ctr, Dept Med Oncol,State Key Lab Oncol South China, Dongfeng Rd East 651, Guangzhou 510060, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2024年 / 47卷 / 08期
关键词：
D O I：
10.1016/j.asjsur.2024.03.149
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：3577 / 3578
页数：2
相关论文
共 50 条
  • [1] Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
    Liu, Min
    Yan, Jiaqing
    Le, Kaidi
    Li, Ying
    Xing, Nianzeng
    Li, Guohui
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [2] Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis
    Oyman, Abdilkerim
    Basak, Mustafa
    Ozcelik, Melike
    Ozyukseler, Deniz Tataroglu
    Isik, Selver
    Yildirim, Mahmut Emre
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (05) : E201 - E207
  • [3] Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Fea, E.
    Vanella, P.
    Miraglio, E.
    Cauchi, C.
    Colantonio, I.
    Denaro, N.
    Di Costanzo, G.
    Garrone, O.
    Granetto, C.
    Occelli, M.
    Ricci, V.
    Vandone, A. M.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer
    Jeong, Yumun
    Lee, Jae Lyun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (03) : 204 - 211
  • [5] The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
    Subudhi, Sumit Kumar
    Han, Weiqing
    Liao, Chih-Yi
    Zhang, Shun
    Dai, Tao
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Yu, Yingying
    Wu, Yingtong
    Li, Qing
    Xu, Ruolan
    Huang, Peng
    Neo, Levin
    Wu, Frank
    Fan, Jean
    Piha-Paul, Sarina A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 133 - 133
  • [6] Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study
    LI, Jian-ri
    Wang, Shian-shiang
    Chen, Chuan-shu
    Yang, Cheng-kuang
    Lu, K. E. V. I. N.
    Cheng, Chen-Li
    Hung, Sheng-Chun
    Chen, Shu-Yen
    Hsu, Chiann Yi
    Chiu, Kun-Yuan
    ANTICANCER RESEARCH, 2022, 42 (10) : 4857 - 4866
  • [7] Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
    Darren M. C. Poon
    Kuen Chan
    S. H. Lee
    T. W. Chan
    Henry Sze
    Eric K. C. Lee
    Daisy Lam
    Michelle F. T. Chan
    BMC Urology, 16
  • [8] Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer
    Caffo, Orazio
    Facchini, Gaetano
    Biasco, Elisa
    Ferrau, Francesco
    Morelli, Franco
    Donini, Maddalena
    Buttigliero, Consuelo
    Calvani, Nicola
    Guida, Annalisa
    Chiuri, Vincenzo Emanuele
    Basso, Umberto
    Mucciarini, Claudia
    Conteduca, Vincenza
    Rossetti, Sabrina
    Veccia, Antonello
    Maines, Francesca
    Kinspergher, Stefania
    De Giorgi, Ugo
    FUTURE ONCOLOGY, 2019, 15 (10) : 1115 - 1123
  • [9] Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience
    Poon, Darren M. C.
    Chan, Kuen
    Lee, S. H.
    Chan, T. W.
    Sze, Henry
    Lee, Eric K. C.
    Lam, Daisy
    Chan, Michelle F. T.
    BMC UROLOGY, 2016, 16
  • [10] Efficacy of Carboplatin and Cabazitaxel in heavily pretreated Patients with metastatic castration-resistant Prostate Cancer
    Strewinsky, N.
    Dyshlovoy, S. A.
    Schuettfort, V. M.
    Oh-Hohenhorst, S. J.
    Tilki, D.
    Graefen, M.
    Bokemeyer, C.
    von Amsberg, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 187 - 187
12345